Wernicke encephalopathy, caused by a lack of vitamin B1, can be reversed if caught early — but doctors frequently miss it because the “classic” warning signs usually don’t all show up.
By disabling the antioxidant shield that tumor cells use to survive, the experimental drug RSO-021 lets a cancer’s own toxic byproducts build up until it destroys itself — with promising early results in a hard-to-treat disease.
Injectable peptides rule the obesity market, but they’re hard to turn into pills. Novo’s new alliance with Orbis targets a class of ring-shaped molecules designed to survive the gut.
Using stem-cell-derived “kidney organoids,” scientists showed that high glucose alone can trigger damaging inflammation — and that blocking specific pathways protected the tissue.
Fayuvi, a one-time gene therapy from Ultragenyx, is the first treatment approved for Sanfilippo syndrome type A — a rare disorder that steadily robs children of the abilities they once had.
The maker of Ozempic and Wegovy is deploying Anthropic’s Claude models across its R&D and engineering — the latest sign that Big Pharma sees AI as a core tool, not an experiment.
The blood-brain barrier blocks most large-molecule drugs from reaching the brain. Novartis is buying Sironax’s delivery technology to get antibodies, proteins and gene therapies through it.
A first-of-its-kind atlas of tiny, overlooked “microproteins” in the human brain uncovered more than 1,000 unknown players — including one that, when lost, saps the energy of the brain’s immune cells.
Kybella is approved only to melt fat under the chin. The FDA is warning that using it elsewhere on the body — an increasingly popular cosmetic trend — has caused serious adverse reactions.
New evidence suggests that for people with one or two small, low-risk polyps removed, waiting longer between follow-up colonoscopies is safe — sparing patients procedures many are getting too often.
In its final Phase 3 analysis, Trutakna (atacicept) essentially stabilized kidney function and cut disease-progression events by 76% in IgA nephropathy — strong data as Vera pushes for full FDA approval.
Pooling 139 trials, researchers found the most effective drug-free treatments for knee osteoarthritis were surprisingly simple: knee braces, water-based therapy and regular exercise — while a common clinic staple ranked near the bottom.